RETAVASE® (reteplase) is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin degrades the fibrin matrix of the thrombus, exerting its thrombolytic action.
To reduce the risk of death and heart failure
in acute STEMI, RETAVASE
Helps break through clots with zero dose calculations
RETAVASE achieved greater than 80% rate of TIMI 2 or 3 flow at 90 minutes in patients with acute STEMI1‑3
In clinical trials, more patients achieved TIMI 3 flow at 90 minutes with RETAVASE 10 + 10 unit vs alteplase (100 mg over 1.5 hours or over 3 hours).1-3
The only fibrinolytic for acute STEMI with non–weight‑based dosing
Have questions? For additional assistance or questions not answered on this website, contact Chiesi USA, Inc.